Your browser doesn't support javascript.
loading
Molecular docking analysis of piperlongumine with different apoptotic proteins involved in Hepatocellular Carcinoma.
Kumar, Ashish; Sharma, Ambika; Handu, Shailendra; Singh, Jagjit; Naithani, Manisha.
Afiliação
  • Kumar A; Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Rishikesh-249203, Uttarakhand, India.
  • Sharma A; Department of Biochemistry, College of Veterinary Science, DUVASU, Mathura-281001, Uttar Pradesh, India.
  • Handu S; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh-249203, Uttarakhand, India.
  • Singh J; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Rishikesh-249203, Uttarakhand, India.
  • Naithani M; Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Rishikesh-249203, Uttarakhand, India.
Bioinformation ; 17(9): 829-833, 2021.
Article em En | MEDLINE | ID: mdl-35539886
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Numerous signalling pathways are involved in hepatocellular carcinoma. Piperlongumine is a potential candidate for the treatment of hepatocellular carcinoma. Therefore, it is of interest to document the molecular docking analysis of piperlongumine with different apoptotic proteins involved in Hepatocellular Carcinoma. Piperlongumine was docked with the HCC targets such as vascular endothelial growth factor (VEGF), epidermal growth factor receptor, Aurora-2, Nuclear factor Kappa-B (NF-KB), Jak2 Kinase, Fibroblast growth factor receptor 4, Bcl-2-like protein 1,Apopain, and Apoptosis regulator Bcl-2 using in-silico technique with the software grid-based ligand docking with energies. Piperlongumine exhibited the highest negative energy value (E-value) of -6.58 kcal/mol with vascular endothelial growth factor receptor 2, followed by -5.46, -5.34, -5.31, and -5.29 kcal/mol with 1M17, 2BMC, 1SVC, 4C61, 4XCU with epidermal growth factor receptor, aurora-2, nuclear factor Kappa-B (NF-KB), Jak2 kinase, and fibroblast growth factor receptor 4 (FGFR4), respectively for further consideration.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article